Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
Evaluation of the reasons for discontinuation of therapy with Janus kinase inhibitors (JAKi) may provide a clue to their more effective use.Objective : to analyze the survival of tofacitinib (TOFA) therapy and the reasons for its discontinuation in rheumatoid arthritis (RA) in real clinical practice...
Saved in:
| Main Authors: | G. I. Gridneva, E. S. Aronova, B. S. Belov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1369 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01) -
NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01) -
Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01) -
Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials"
by: YanRan Qiu, et al.
Published: (2025-03-01) -
Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)